Evotec Receives Pre-Clinical Milestone with Boehringer Ingelheim
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Evotec AG announced that its research alliance with Boehringer Ingelheim has reached a milestone in November triggering revenues of € 4.0 m to Evotec.
Dr Mario Polywka, Chief Operating Officer of Evotec commented: “This is the twenty-first milestone achieved as part of our alliance with Boehringer Ingelheim and represents a third oncology compound transitioning into pre-clinical development of which one is already in Phase I clinical trials. Our collaboration with Boehringer Ingelheim continues to support Evotec’s overall strategy of building up a pipeline of assets of which we have interest in future upside.”
